Drug Profile

ENTR 501

Alternative Names: ENTR-501

Latest Information Update: 28 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Mitochondrial myopathies
New Molecular Entity No
Available For Licensing Yes - Mitochondrial myopathies

28 Feb 2024 No recent reports of development identified for preclinical development in Mitochondrial-myopathies in USA
12 Dec 2022 ENTR 501 is available for licensing as of 31 Jan 2020. https://www.entradatx.com/pipeline
24 Apr 2020 ENTR 501 receives Orphan Drug status for Mitochondrial myopathies in USA, prior to April 2020 (Entrada Therapeutics pipeline, April 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com